Opioid alkaloids and casomorphin peptides decrease the proliferation of prostatic cancer cell lines (LNCaP, PC3 and DU145) through a partial interaction with opioid receptors

European Journal of Pharmacology

Volumn 335, Issue 2-3, 1997, Pages 255-265

  Kampa, Marilenna ^a   Bakogeorgou, Efstathia ^a   Hatzoglou, Anastassia ^a,c   Damianaki, Athina ^a   Martin, Pierre Marie ^b   Castanas, Elias ^a,b  

^a UNIVERSITY OF CRETE   (Greece)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSERM   (France)

Author keywords

Opioid receptor; Opioid receptor; Opioid receptor; Casein; Casomorphin; Cell line, LNCaP, DU145, C3; Cell proliferation; Prostate cancer; Receptor subtype

Indexed keywords

BETA CASOMORPHINE DERIVATIVE; DIPRENORPHINE; ENKEPHALIN[2 DEXTRO ALANINE 5 DEXTRO LEUCINE]; ETHYLKETAZOCINE; ETORPHINE; LEUCINE ENKEPHALIN[2 DEXTRO SERINE 6 THREONINE]; MORPHINE; OPIATE; OPIATE ANTAGONIST; OPIATE RECEPTOR; RECEPTOR SUBTYPE;

ARTICLE; CELL CULTURE; CELL GROWTH; CELL LINE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

BINDING SITES; CASEINS; CELL DIVISION; CELL SURVIVAL; ENKEPHALINS; ETHYLKETOCYCLAZOCINE; HUMANS; LIGANDS; MALE; MORPHINANS; NARCOTIC ANTAGONISTS; NARCOTICS; PROSTATIC NEOPLASMS; RECEPTORS, OPIOID; TUMOR CELLS, CULTURED;

EID: 0030823262     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01213-2     Document Type: Article

References (52)

1. Aylsworth C.F., Hodson C.A., Meites J. Opiate antagonists can inhibit mammary tumor growth in rats. Proc. Soc. Exp. Biol. Med. 161:1979;18-20.
2. Boring C.C., Squires T.S., Tong T. Cancer statistics, 1991. CA Cancer J. Clin. 41:1991;19-36.
3. Brantl V., Teschemacher H., Henschen A., Lottspeich F. Novel opioid peptides derived from casein (β-casomorphins): I. Isolation from bovine casein peptone. Hoppe-Seyler's Z. Physiol. Chem. 360:1979;1211-1216.
4. Carter H.B., Coffey D.S. The prostate: An increasing medical problem. Prostate. 16:1990;39-48.
5. Carter B.S., Carter H.B., Isaacs J.T. Epidemiologic evidence regarding predisposing factors to prostate cancer. Prostate. 16:1990;187-197.
6. Carter H.B., Piantadosi S., Isaacs J.T. Clinical evidence for and implications of the multistep development of prostate cancer. J. Urol. 143:1990;742-746.
7. Castanas E., Giraud P., Audigier Y., Drissi R., Boudouresque F., Conte-Devolx B., Oliver C. Adrenal medullary opiate receptors: Pharmacological characterization in bovine adrenal medulla and a human pheochromocytoma. Mol. Pharmacol. 25:1984;38-45.
8. Castanas E., Bourhim N., Giraud P., Boudouresque F., Cantau P., Oliver C. Interaction of opiates with opioid binding sites in the bovine adrenal medulla: I Interaction with delta and mu sites. J. Neurochem. 45:1985;677-687.
9. Castanas E., Bourhim N., Giraud P., Boudouresque F., Cantau P., Oliver C. Interaction of opiates with opioid binding sites in the bovine adrenal medulla: II Interaction with kappa sites. J. Neurochem. 45:1985;688-699.
10. Crowe R., Chapple C.R., Burnstock G. The human prostategland: A histochemical and immunohistochemical study of neuropeptodes, serotonin, dopamine beta-hydroxylase and acetylcholinesterase in autonomic nerves ganglia. Br. J. Urol. 68:1991;53-61.
11. Dupont J., White P.J., Feldman E.B. Saturated and hydrogenated fats in food in relation to health. J. Am. Coll. Nutr. 10:1991;577-592.
12. Giovannucci E. Epidemiologic characteristics of prostate cancer. Cancer. 75:1995;1766-1777.
13. Gkonos P.J., Krongrad A., Roos B.A. Neuroendocrine peptides in the prostate. Urol. Res. 23:1995;81-87.
14. Gu J., Polak J.M., Probert L., Islam K.N., Marangos P.J., Mina S., Adrian T.E., McGregor G.P., O'Shaughnessy D.J., Bloom S.R. Peptidergic innervation of the human male genital tract. J. Urol. 130:1983;386-391.
15. Hanks, G.E., Myers, C.E., Scardino, P.T., 1993. Cancer of the prostate. In: DeVita, V.T., Hellman, S., Rosenberg, S.A. (Eds.), Cancer: Principle and Practice of Oncology. J.B. Lippincott Co., Philadelphia.
16. Hatzoglou A., Romain S., Dalapascha H., Castanas E. Acidification reveals a greater number of epidermal growth factor receptors in human membrane preparations. Clin. Chim. Acta. 227:1994;97-109.
17. Hatzoglou A., Gravanis A., Zoumakis E., Margioris A., Castanas E. Identification and characterization of opioid binding sites present in the Ishikawa human endometrial adenocarcinoma cell line. J. Clin. Endocrinol. Metab. 80:1995;418-423.
18. Hatzoglou A., Ouafik L.H., Bakogeorgou E., Thermos K., Castanas E. Morphine cross-reacts with somatostatin receptor SSTR2 in the T47D human breast cancer cell line, and decreases cell proliferation. Cancer Res. 65:1995;5632-5636.
19. Hatzoglou A., Bakogeorgou E., Castanas E. The antiproliferative effect of opioid agonists on the T47D human breast cancer cell line, is partially mediated through opioid receptors. Eur. J. Pharmacol. 296:1996;199-207.
20. Hatzoglou A., Bakogeorgou E., Hatzoglou C., Martin P.-M., Castanas E. Antiproliferative and Receptor binding properties of α- and β-casomorphin peptides, in the T47D human breast cancer cell line. Eur. J. Pharmacol. 310:1996;217-223.
21. Hatzoglou A., Margioris A., Bakogeorgou E., Gravanis A., Castanas E. Identification, characterization and localisation of corticotropin-releasing hormone receptors in human placenta. Life Sci. 59:1996;1871-1879.
22. Heiber M., Docherty J.M., Shah G., Nguyen T., Cheng R., Heng H.H., Marchese A., Tsui L.C., Shi X., George S.R. Isolation of three novel human genes encoding G protein-coupled receptors. DNA Cell Biol. 14:1995;25-35.
23. Horoszewicz J.S., Leong S.S., Kawinski E., Karr J.P., Rosenthal H., Ming Chu T., Mirand E.A., Murphy G.P. LNCaP model of human prostatic carcinoma. Cancer Res. 43:1983;1809-1818.
24. Jen P.Y., Dixon J.S. Development of peptide-containing nerves in the human fetal prostate gland. J. Anat. 187:1995;169-179.
25. Kaighn M.E., Naayan K.S., Ohnuki Y., Lechner J.F., Jones L.W. Establishment and characterisation of a human prostatic carcinoma cell line (PC3). Invest. Urol. 17:1979;16-23.
26. Kampa M., Loukas S., Hatzoglou A., Martin P., Martin P.-M., astanas E. Identification of a novel opioid peptide (Tyr-Val-Pro-Phe-Pro) derived from human alphaS1 casein (αS1-casomorphin, and αS1-casomorphin-amide). Biochem. J. 319:1996;903-908.
27. Kikuchi Y., Kita T., Miyauchi M., Kizawa I., Oomori K., Kato K. Effects of naloxone on human ovarian cancer cell growth in vitro and in vivo. Jpn. J. Cancer Res. 78:1987;519-525.
28. Kita T., Kikushi Y., Ooomori K., Nagata I. Effects of opioid peptides on the tumoricidal activity of spleen cells from nude mice with or without tumors. Cancer Detect. Prev. 16:1992;211-214.
29. Krieger, D.T., Margioris, A.N., Liotta, A.S., Shaha, C., Gerandai, I., Pintar, J., Bardin, C.W., 1984. Pro-opiomelanocortin-derived peptides in the rodent male reproductive tract. In: Delitala, G., Motta, M., Serio, M. (Eds.). Raven Press, New York, pp. 223-235.
30. Le Marchand L., Kolonel L.N., Wilkens L.R., Myers B.C., Hirohata T. Animal fat consumption and prostate cancer: A prospective study in Hawaii. Epidemiology. 5:1994;276-282.
31. Lottspeich F., Henchen A., Brantl V., Teschemacher A. Novel opioid peptides derived from casein (β-casomorphins): III. Synthetic peptides corresponding to components of bovine casein peptone. Hoppe-Seyler's Z. Physiol. Chem. 361:1980;1835-1839.
32. Loukas S., Varoucha D., Zioudrou C., Streaty R.A., Klee W.A. Opioid activities and structures of α-casein-derived exorphins. Biochemistry. 22:1983;4567-4573.
33. Mahe S., Tome D., Dumontier A.M., Desjeux J.F. Absorption of intact beta-casomorphins (beta-CM) in rabbit ileum in vitro. Reprod. Nutr. Dev. 29:1989;725-733.
34. Maneckjee R., Biswas R., Vonderhaar B.K. Binding of opioids to human MCF-7 breast cancer cells, and their effects on growth. Cancer Res. 50:1990;2234-2238.
35. Meisel H. Chemical characterisation and opioid activity of an exorphin isolated from in vivo digests of casein. FEBS Lett. 196:1986;223-227.
36. Morphy J.B., Emmott R.C., Hicks L.L., Walsh P.C. Estrogen receptors in the human prostate, seminal vesicle, epididymis, testis, and genital skin: A marker for estrogen responsive tissues. J. Clin. Endocrinol. Metab. 50:1980;938-948.
37. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:1973;53-63.
38. Munson P.J., Rodbard D. LIGAND: A versatile computerized approach to characterization of ligand-binding systems. Anal. Biochem. 107:1980;220-239.
39. Noordzij M.A., van Steenbrugge G.J., van der Kwast T.h., Schroder F.H. Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate. Urol. Res. 22:1995;333-341.
40. Nyberg F., Lieberman H., Lindstrom L.H., Lirenas S., Koch G., Terenius L. Immunoreactive beta casomorphin-8 in cerebrospinal fluid from pregnant and lactating women: Correlation with plasma levels. J. Clin. Endocrinol. Metab. 68:1989;283-289.
41. Papsidero L.D., Kuriyama M., Wang M.C., Horoszwicz J.S., Leong S.S., Valenzuela L., Murphy G.P., Chu T.M. Prostate antigen: A marker for human prostate epithelial cells. J. Natl. Cancer Inst. 66:1981;37-42.
42. Reubi J.C. Central nervous system-mediated growth inhibition of a rat prostate carcinoma by an opioid. J. Endocrinol. 107:1985;247-250.
43. Scholar E.M., Violi L., Hexum T.D. The antimetastatic effect of enkephalin-like peptides. Cancer Lett. 35:1987;133-138.
44. Stone K.R., Mickey R.R., Wuderly H., Mickey J.H., Paulson D.F. Isolation of a human prostate carcinoma cell line (DU 145). Int. J. Cancer. 21:1978;274-281.
45. Tainio H. Peptidergic innervation of the human prostate, seminal vesicle and vas deferens. Acta Histochem. 97:1995;113-119.
46. Tatoud R., Degeorges A., Prevost G., Hoepffner J.L., Gauville C., Millot G., Thomas F., Calvo F. Somatostatin receptors in prostate tissues and derived cell cultures, and the in vitro growth inhibitory effect of BIM-23014 analog. Mol. Cell. Endocrinol. 113:1995;195-204.
47. Tome D., Dumontier A.M., Hautefeuille M., Desjeux J.F. Opiate activity and transepithelial passage of intact beta-casomorphins in rabbit ileum. Am. J. Physiol. 253:1987;G737-744.
48. Vilner B.J., John C.S., Bowen W.D. Sigma-1 and sogma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res. 55:1995;408-413.
49. Zagon I.S., McLaughlin P.J. Naloxone prolongs the survival time of mice treated with neuroblastoma. Life Sci. 28:1981;1095-1102.
50. Zagon I.S., McLaughlin P.J. Naltrexone modulates tumor response in mice with neuroblastoma. Science (Wash. DC). 221:1983;671-673.
51. Zagon I.S., McLaughlin P.J., Goodman S.R., Rhodes R.E. Opioid receptors and endogenous opioids in diverse human and animal cancers. J. Natl. Cancer Inst. 79:1987;1059-1065.
52. Zagon I.S., Goodman S.R., McLaughlin P.J. Characterization of zeta (ζ): A new opioid receptor involved in growth. Brain Res. 482:1989;297-305.